Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

176
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
176
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

206
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
206
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

209
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
209
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

245
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
245
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

1.2K
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
1.2K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Asiatic acid promotes CD8<sup>+</sup> T cell-mediated antitumor immunity by targeting HDAC8/CXCL10 axis in hepatocellular carcinoma.

Acta pharmacologica Sinica·2026
Same author

Mitochondria-derived peptides in liver disease: Emerging regulators of hepatic metabolism and therapeutic targets.

Hepatology communications·2026
Same author

Dynamics of Serum Hepatitis B Virus Nucleic Acids in Patients With Chronic Hepatitis B After Stopping Nucleos(t)ide Analogs Reveal Delayed Rebound of Hepatitis B Virus RNA.

Journal of medical virology·2025
Same author

Improving Performance of Quasi-2D Perovskite Light-Emitting Diodes by Solvent Atmospheric Post-Treatment.

ACS applied materials & interfaces·2025
Same author

Non-coding RNAs in alcohol-associated liver disease.

Liver research (Beijing, China)·2025
Same author

Pd-Catalyzed Tandem Reaction of [1,1'-Biaryl]-2,2'-dimethylnitriles with Arylboronic Acids: Synthesis of 7-Aryl-2<i>H</i>-azepin-2-ones.

The Journal of organic chemistry·2025
Same journal

Navigating Chronic Pain in Patients with Cirrhosis: Unique Analgesic Considerations and Non-Pharmacologic Options.

Current hepatology reports·2026
Same journal

AIH Therapy: Beyond First‑Line.

Current hepatology reports·2026
Same journal

Transient Elastography and Fibroscan: Stethoscope of a Hepatologist in Today's World.

Current hepatology reports·2026
Same journal

Met-ALD and ALD- Does Differentiating These Impact Management and Clinical Outcomes?

Current hepatology reports·2025
Same journal

Outcomes in Cirrhosis-Related Refractory Ascites with Emphasis on Palliative Care: Single-Centre Experience and Literature Review.

Current hepatology reports·2025
Same journal

Hepatic Hydrothorax: A Review.

Current hepatology reports·2025
查看所有相关文章

相关实验视频

Updated: Jan 12, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.9K

酒精相关性肝炎:将病理生理学转化为有针对性的临床试验

Jing Ma1, Hui Gao1, Ge Zeng1,2

  • 1Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, 702 Rotary Circle, Indianapolis, IN 46202 USA.

Current hepatology reports
|October 30, 2025
PubMed
概括
此摘要是机器生成的。

酒精相关性肝炎 (AH) 是一种严重的肝病,治疗方法有限. 研究正在探索针对氧化应激,再生和肠道健康的新疗法,以改善酒精相关肝炎患者的治疗结果.

关键词:
与酒精有关的肝炎.临床试验临床试验是指临床试验的临床试验.治疗目标 治疗目标

更多相关视频

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.6K
Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration
10:42

Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration

Published on: May 13, 2016

9.5K

相关实验视频

Last Updated: Jan 12, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.9K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.6K
Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration
10:42

Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration

Published on: May 13, 2016

9.5K

科学领域:

  • 肝病学 肝病学是一种肝病学.
  • 胃肠病学 胃肠病学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 酒精相关性肝炎 (AH) 是一种严重的酒精相关性肝病.
  • 它的特点是高的短期死亡率和缺乏有效治疗方法.

研究的目的:

  • 审查 AH 病原体背后的机制.
  • 评估过去和新兴的临床试验,以开发有针对性的治疗方法.

主要方法:

  • 对AH的机械见解的综合.
  • 对各种治疗点的临床试验数据的评估.

主要成果:

  • 甲状腺炎的发病包括肝毒性,氧化应激,炎症,再生障碍和肠肝轴障碍.
  • 以前针对炎症或亡的试验没有显示出生存益处,并引发了安全问题.
  • 新兴疗法侧重于减轻氧化应激,增强再生和恢复肠道完整性,包括IL-22,G-CSF,益生菌,FMT,菌和FXR激动剂等药物.

结论:

  • 了解AH生物学为基于机制的治疗策略提供了基础.
  • 将肝病学与成医学相结合,并使用分层试验设计,对于推进有效治疗至关重要.